By Conjoint Professor Dedee Frances Murrell

Journal articles

Rademaker M; Jarrett P; Murrell DF; Sinclair RD; Pasfield L; Poppelwell D; Shumack S, 2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, 65, pp. e145 - e155, http://dx.doi.org/10.1111/ajd.14308

Bai H; Lin G; Kantor J; Elston D; Grant-Kels JM; Murrell DF; Murase JE, 2024, 'Dermatology Journal Advisory Boards and editorial independence', Jaad International, 16, pp. 224 - 236, http://dx.doi.org/10.1016/j.jdin.2023.08.001

Akbarialiabad H; Grant-Kels JM; Murrell DF, 2024, 'Letter to the editor in reply to “A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists”', Clinics in Dermatology, 42, pp. 526 - 527, http://dx.doi.org/10.1016/j.clindermatol.2024.07.002

Koszegi B; Stone C; Ishii N; Hashimoto T; Murrell DF, 2024, 'Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions', Journal of the European Academy of Dermatology and Venereology, 38, pp. e747 - e749, http://dx.doi.org/10.1111/jdv.19863

Korte EWH; Pasmooij AMG; Bolling MC; Hickey S; Hussain S; Kiritsi D; Kottner J; Prinsen CAC; Sauvestre A; Sendin G; Spuls PI; Tarrats N; Wally V; Welponer T; Laimer M; Van Den Akker PC; Bardhan A; Bataille P; Bodemer C; Bolling M; Bruckner A; Chiaverini C; Clemett V; Collins C; Colmant C; De Rosa L; Duipmans J; Ebens C; Fernandez MF; Gorell E; Guez S; Has C; Hsu CK; Jain R; Kenny T; Kern JS; Khanna D; Kitzmüller S; Lara-Corrales I; Lee M; Li W; Lospalluti L; Marinkovich MP; Martinez A; Mellerio J; Moss C; Mullins O; Murrell D; Ott H; Palisson F; Paller A; Pasmooij M; Petrof G; Pope E; Salamon G; Salas-Alanis J; Salavastru C; Scherer S; Schräder N; Sprecher E; Spreitzer C; Tarrats N; Wertheim-Tysarowska K; Zahn T, 2024, 'Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa', British Journal of Dermatology, 191, pp. 463 - 465, http://dx.doi.org/10.1093/bjd/ljae200

Murrell DF; Ferrucci SM; Foti C; Perez-Garcia B; Lapeere H; Calzavara-Pinton P; Fougerousse A-C; Wu J; Ardeleanu M; Bosman K, 2024, '634 - Patient-reported outcomes and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one year into the GLOBOSTAD multinational prospective observational study', British Journal of Dermatology, 191, pp. ljae266.016, http://dx.doi.org/10.1093/bjd/ljae266.016

Murrell DF; Caux F; Patsatsi A; Hagino O; Rudnicka L; Vassileva S; Uzun S; Ye J; Yen K; Arora P; Gourlay SG; Joly P; Werth VP, 2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, 144, pp. 1762 - 1771.e6, http://dx.doi.org/10.1016/j.jid.2024.02.023

Walter S; Murrell DF, 2024, 'Gender equity in academic dermatology: Problems aplenty, yet paths ahead', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1504 - 1513, http://dx.doi.org/10.1111/jdv.20027

Cowan TL; Sundberg JP; Roopenian DC; Sproule TJ; Murrell DF, 2024, 'Phenotypic differences in intermediate generalized junctional epidermolysis bullosa with homozygous LAMC2 mutation and a potential genetic modifier', Journal of the European Academy of Dermatology and Venereology, 38, pp. e719 - e721, http://dx.doi.org/10.1111/jdv.19859

Murrell DF; Joly P; Werth VP; Ujiie H; Worm M; Mangold AR; Avetisova E; Maloney J; Laws E; Mortensen E; Dubost-Brama A; Shabbir A, 2024, 'Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT (Advances in Therapy, (2024), 41, 7, (2991-3002), 10.1007/s12325-024-02810-3)', Advances in Therapy, 41, pp. 3014 - 3015, http://dx.doi.org/10.1007/s12325-024-02886-x

Murrell DF; Joly P; Werth VP; Ujiie H; Worm M; Mangold AR; Avetisova E; Maloney J; Laws E; Mortensen E; Dubost-Brama A; Shabbir A, 2024, 'Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT', Advances in Therapy, 41, pp. 2991 - 3002, http://dx.doi.org/10.1007/s12325-024-02810-3

Ferrucci SM; Calzavara-Pinton P; Murrell DF; Fougerousse A-C; Karlova I; Lapeere H; Holzer G; Al-Ahmad M; Chu C-Y; Foti C; Perez-Garcia B; Petrova A; Wu J; Ardeleanu M; Bosman K, 2024, 'Physician-assessed effectiveness, patient-reported outcomes, and safety in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational prospective observational study', BRITISH JOURNAL OF DERMATOLOGY, 191, pp. I56 - I57, http://dx.doi.org/10.1093/bjd/ljae090.115

Caux F; Patsatsi A; Karakioulaki M; Antiga E; Baselga E; Borradori L; Caproni M; Cardones AR; Chandran NS; Dräger S; Drenovska K; Goebeler M; Günther C; Hofmann SC; Ioannides D; Joly P; Marinović B; Mariotti EB; Marzano AV; Morel KD; Murrell DF; Prost C; Sárdy M; Setterfield J; Skiljevic D; Uzun S; Vassileva S; Zambruno G; Schmidt E, 2024, 'S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1006 - 1023, http://dx.doi.org/10.1111/jdv.19880

Schmidt E; Ludwig RJ; Caux F; Payne AS; Sadik CD; Hashimoto T; Murrell DF, 2024, 'Editorial: Pemphigus and pemphigoid diseases: in memoriam Detlef Zillikens', Frontiers in Immunology, 15, pp. 1426834, http://dx.doi.org/10.3389/fimmu.2024.1426834

Murrell DF, 2024, 'Palmar Erythema Associated with Natalizumab in a Patient with Multiple Sclerosis', Clinical Dermatology & Therapy, 10, pp. 1 - 4, http://dx.doi.org/10.24966/cdt-8771/100133

Koszegi B; Murrell DF, 2024, 'Dapsone for the management of severe epidermolysis bullosa simplex: A case report and evidence for a repurposing trial', Journal of the European Academy of Dermatology and Venereology, 38, pp. e420 - e421, http://dx.doi.org/10.1111/jdv.19646

Murrell DF; Daneshpazhooh M, 2024, 'Impairment of sexual function in patients with pemphigus', Journal of the European Academy of Dermatology and Venereology, 38, pp. 643 - 644, http://dx.doi.org/10.1111/jdv.19882

Navarrete-Dechent C; Ashique KT; Ingram JR; Rudnicka L; Gilaberte Y; Ring J; Murrell DF; Elston D; Thiers BH, 2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, 90, pp. 707 - 710, http://dx.doi.org/10.1016/j.jaad.2023.11.038

Ferrucci SM; Calzavara-Pinton P; Murrell DF; Fougerousse A-C; Karlova I; Lapeere H; Holzer G; Al-Ahmad M; Chu C-Y; Foti C; Pérez-García B; Wu J; Ardeleanu M; Bosman K, 2024, '531 - Physician-assessed effectiveness and patient-reported outcomes in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational prospective observational study', British Journal of Dermatology, 190, pp. ii34 - ii34, http://dx.doi.org/10.1093/bjd/ljad498.036

Labbouz S; Khan S; Gohara M; Lucas J; Sarkar R; Murrell DF; Dodiuk-Gad RP, 2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women S Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125

Vassileva S; Murrell DF; Culton DA; Ujiie H; Hertl M; Goebeler M; Sinha AA; Schmidt E; Stoykov I; Verheesen P; Borradori L; Werth VP; Joly P, 2024, 'Overview of Clinical Trials With Efgartigimod in Autoimmune Blistering Diseases: Pemphigus Vulgaris and Pemphigus Foliaceus (ADDRESS and ADDRESS+) and Bullous Pemphigoid (BALLAD and BALLAD+)', SKIN The Journal of Cutaneous Medicine, 8, pp. s345, http://dx.doi.org/10.25251/skin.8.supp.345

Stone C; Murrell DF, 2024, 'A Case of Hidradenitis Suppurativa Responsive to Testosterone Replacement Therapy', Indian Dermatology Online Journal, 15, pp. 854 - 855, http://dx.doi.org/10.4103/idoj.idoj_653_23

Stone C; Bertolotti A; Davey L; Murrell DF, 2024, 'Atypical fixed drug eruption in confetti due to paracetamol', Dermatologica Sinica, 42, pp. 160 - 161, http://dx.doi.org/10.4103/ds.DS-D-23-00161

Stone C; Bak G; Oh D; Zhao C; Venugopal S; Kumar K; Murrell DF, 2024, 'Environmental triggers of pemphigus vulgaris and bullous pemphigoid: a case control study', Frontiers in Medicine, 11, http://dx.doi.org/10.3389/fmed.2024.1441369

Murrell DF; Weinberg JM; Yamauchi PS; Abdelmaksoud A; Grabbe S; Goldust M, 2024, 'Predatory Conferences and Journals in Dermatology Are Black Widow Parties', Skinmed, 22, pp. 407 - 408

Tseng H; Stone C; Murrell DF, 2024, 'Scoring Criteria for Autoimmune Bullous Diseases: Utility, Merits, and Demerits', Indian Dermatology Online Journal, 15, pp. 732 - 738, http://dx.doi.org/10.4103/idoj.idoj_611_23

Tseng H; Murrell DF, 2024, 'The potential of Bruton’s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease', Expert Opinion on Pharmacotherapy, 25, pp. 1657 - 1665, http://dx.doi.org/10.1080/14656566.2024.2393280

Bruckner A; Kiritsi D; Murrell D; Lee LW; Sprecher E; Maher L; Löwe S; Kern J, 2024, '274 Oleogel-S10 reduces dressing changes burden and associated costs in patients with epidermolysis bullosa', Journal of Investigative Dermatology, 144, pp. S47 - S47, http://dx.doi.org/10.1016/j.jid.2024.06.290

Simpson E; Gooderham M; Kircik L; Armstrong AW; Schlesinger T; Del Rosso JQ; Murrell DF; Thng S; Szepietowski JC; Veverka KA; Kaoukhov A, 2024, '53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial', Journal of the American Academy of Dermatology, 91, pp. ab194, http://dx.doi.org/10.1016/j.jaad.2024.07.773

Murrell DF; Ferrucci SM; Foti C; Perez-Garcia B; Lapeere H; Fougerousse A-C; Wu J; Ardeleanu M; Bosman K, 2024, '53738 Patient-Reported Outcomes and Safety in Adolescent and Adult Atopic Dermatitis Patients Treated with Dupilumab: Real-World Insights One Year into the GLOBOSTAD Multinational Prospective Observational Study', Journal of the American Academy of Dermatology, 91, pp. ab276, http://dx.doi.org/10.1016/j.jaad.2024.07.1098

Haidari H; Geremew A; Cowin A; Vasilev K; Murrell D; Kopecki Z, 2024, '553 Development of Bacteria Activated Stimuli-Response Dressing for Management of Infection in Epidermolysis Bullosa', Journal of Investigative Dermatology, 144, pp. S324 - S324, http://dx.doi.org/10.1016/j.jid.2024.10.566

Wilson BN; Shah R; Ufongene C; Sun MD; Diaz AF; Murrell DF; Murase JE, 2024, 'Evaluation of Skin of Color Publication Trends over the Past Two Decades in the Journal of the American Academy of Dermatology (vol 89, pg 614, 2023)', JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 90, pp. 881 - 881, http://dx.doi.org/10.1016/j.jaad.2024.01.005

Koszegi B; Wilson A; Stone C; Satge F; Cowan TL; Murrell DF, 2023, 'Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: A 30-month experience', Clinical and Experimental Dermatology, 48, pp. 1266 - 1269, http://dx.doi.org/10.1093/ced/llad215

Guttman-Yassky E; Bahadori L; Brooks L; Clark KL; Grindebacke H; Ho CN; Katial R; Pham TH; Walton C; Datto CJ, 2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195

Kircik LH; Alonso-Llamazares J; Bhatia N; Bukhalo M; Devani AR; Draelos ZD; Dubois J; Gooderham MJ; Kempers SE; Lain E; Lee M; Moore A; Murrell DF; Papp KA; Pariser DM; Sinclair R; Zirwas M; Burnett P; Higham RC; Krupa D; Berk DR, 2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182

Yale M; Dunn P; Strong R; Davies I; Gallu L; Joly P; Murrell DF; Werth VP; Payne AS, 2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673

Wilson BN; Shah R; Sun MD; Diaz AF; Murrell DF; Murase JE, 2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036

Stone C; Sheriff T; Liang Y; Murrell DF, 2023, 'Immunisation status during biologic therapy for hidradenitis suppurativa and psoriasis', JEADV Clinical Practice, 2, pp. 549 - 552, http://dx.doi.org/10.1002/jvc2.182

Singh S; Kirtschig G; Anchan VN; Chi CC; Taghipour K; Boyle RJ; Murrell DF, 2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4

Wang MA; Wilson A; Murrell DF, 2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487

Bunick CG; Teng JMC; Guenthner S; Marathe K; Kempers S; Eads K; Castelo-Soccio L; Mendelsohn AM; Raiz J; Murrell DF, 2023, 'Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study', Clinical and Experimental Dermatology, 48, pp. 765 - 769, http://dx.doi.org/10.1093/ced/llad105

Mosallaei D; Murrell DF; Grant-Kels JM, 2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011

Silverberg JI; Bissonnette R; Kircik L; Murrell DF; Selfridge A; Liu K; Ahluwalia G; Guttman-Yassky E, 2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914

Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; McDowell PJ; Johal J; Heaney LG; Murrell D; Stone MN; Yue H; Stone JH, 2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5

Murrell D; Bruckner AL; Sprecher E; Kiritsi D; Maher L; Cunningham T; Kern JS, 2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, pp. ljad113.144, http://dx.doi.org/10.1093/bjd/ljad113.144

Teng J; Paller AS; Bruckner AL; Murrell DF; Mellerio JE; Bodemer C; Martinez AE; Lugo-Somolinos A; Sprecher E; Laimer M; Wally V; Chan YM; Lin SY; Spellman M; Bauer JW, 2023, 'Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial', Journal of Drugs in Dermatology, 22, pp. 599 - 604, http://dx.doi.org/10.36849/JDD.7108

Murrell DF; Teng JMC; Guenthner S; Marathe K; Kempers S; Eads K; Castelo-Soccio L; Mendelsohn AM; Raiz J; Bunick CG, 2023, 'Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis', Clinical and Experimental Dermatology, 48, pp. 623 - 630, http://dx.doi.org/10.1093/ced/llad033

Marathe K; Teng JMC; Guenthner S; Bunick CG; Kempers S; Eads K; Castelo-Soccio L; Mendelsohn AM; Raiz J; Murrell DF, 2023, 'Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study', Dermatology and Therapy, 13, pp. 1255 - 1264, http://dx.doi.org/10.1007/s13555-023-00923-1

Cowan TL; Ho G; Daniel BS; Murrell DF, 2023, 'Use of a hybrid teledermatology model in an Australian tertiary hospital during the COVID-19 pandemic', Jaad International, 11, pp. 33 - 34, http://dx.doi.org/10.1016/j.jdin.2022.03.016

Tada Y; Takeoka S; Spelman L; Murrell D; Wu J; Zoob P; Bosman K; Chu C-Y; Chung W-H, 2023, 'ISID0459 - Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', , http://dx.doi.org/10.26226/m.641999e770c3630019098d8e

Back to profile page